Bioeq AG is a Swiss biopharmaceutical joint venture between Polpharma Biologics Group and Formycon and is based in Zug. We license, develop and commercialise a biosimilar, which is a successor product of Lucentis® (ranibizumab), a successful branded biopharmaceutical.
We are a young and dynamic company, supported by an international network of experts. Bioeq AG out-licenses its products to established international pharmaceutical companies who ensure local distribution in each territory.
We are currently not hiring
Press Release Bioeq AG – EC Approval FYB/Ranivisio 29.08.2022
Press Release Bioeq AG – FDA approves CIMERLI, the first biosimilar interchangeable with Lucentis 03.08.2022
Press Release Bioeq AG – GRANT OF MARKETING AUTHORISATION IN UK 17.05.2022
Press Release Bioeq AG and MS Pharma 14.12.2021
Press Release Bioeq AG and Teva 28.06.2021
Phone: +41 44 533 41 00